Terray Therapeutics rakes in $120M for AI-powered small-molecule drug development

(October 22, 2024) by Kyt Dotson.

Terray Therapeutics, a biotechnology company using artificial intelligence to accelerate the development of small-molecule drugs, said today it has raised $120 million in a Series B fundraising to enhance its AI platform.

New investor Bedford Ridge Capital and existing investor NVentures, Nvidia Corp.’s venture capital arm, led the funding round. The round also attracted investments from Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. This new financing brings the total raised by the company to more than $200 million.